Roots Sustainable Agricultural Technologies Ltd Appendix 4E Preliminary final report

1. Company details

Name of entity: Roots Sustainable Agricultural Technologies Ltd

ARBN: 619 754 540

Reporting period: For the year ended 31 December 2021 Previous period: For the year ended 31 December 2020

2. Results for announcement to the market

		_	31-Dec-21	31-Dec-20
		_	US\$'000	US\$'000
Revenues from ordinary activities	UP	75%	187	107
Loss from ordinary activities after tax attributable to the owners of Roots Sustainable Agricultural Technologies Ltd	down	28%	2,319	3,202
Loss for the year attributable to the owners of Roots Sustainable Agricultural Technologies Ltd	down	28%	2,319	3,202
Dividends				
			Amount per security Cents	Franked amount per security Cents

Not applicable.

Additional Appendix 4E disclosure requirements can be found in the notes to the Roots Sustainable Agricultural Technologies Ltd's financial statements.

3. Net tangible assets

	Reporting period U.S. dollars	Previous period U.S. dollars
Net tangible assets per ordinary security	0.000104	0.000453

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

Roots Sustainable Agricultural Technologies Ltd Appendix 4E Preliminary final report

6. Details of associates and joint venture entities

percentage holding		Contribution to profit/(loss)		
Reporting period %	Previous	Reporting	Previous	
	period	period	period	
	%	\$'000	\$'000	

Reporting entity's

Name of associate / joint venture

Not applicable.

7. Audit qualification or review

The Preliminary Final Report has been prepared in accordance with ASX Listing Rule 4.3A and has been derived from the unaudited Annual Financial Report for the year ended 31 December 2021. The Annual Financial Report is in the process of being audited and is expected to be made available on or before 31 March 2022.

8. Attachments

The unaudited Preliminary Final Report of Roots Sustainable Agricultural Technologies Ltd for the year ended 31 December 2021 is attached.

9. Signed

Signed Date: 28 February 2022

Boaz Wachtel Executive Chairman Beit Halevi Roots Sustainable Agricultural Technologies Ltd
ARBN 619 754 540

Preliminary Final Report – 31 December 2021

Roots Sustainable Agricultural Technologies Ltd Corporate Directory 31 December 2021

Directors Boaz Wachtel (Executive Chairman and CEO)

Sharon Devir (Executive Director)

Adam Blumenthal (Non-Executive Director)
Graeme Smith (Non-Executive Director)
Dafna Shalev-Flamm (Non-Executive Director)
James Ellingford (Non-Executive Director)

Peter Hatfull (Non-Executive Director) (appointed 23 July 2020)

Company secretary Sarah Smith

Registered officeC/- Mirador Corporate Pty Ltd

Suite 2, 1 Altona Street West Perth WA 6005

Telephone: +61 8 6559 1792

Principal place of business Hamezach 1 Str.

Kefar Vitkin Israel

Share registry Automic Share Registry

Level 2, 267 St Georges Terrace

Perth WA 6000

Telephone: 1300 288 664

Auditor BDO - Tel Aviv

Amot Bituach House Bldg.

B 48 Derech Menachem Begin Rd

Tel Aviv Israel

Solicitors Australian Legal Advisor

Steinepreis Paganin

Level 4, The Read Buildings

16 Milligan Street Perth WA 6000

Israeli Legal Advisor

GKH Law Offices One Azrieli Center Round Building Menachem Begin St. Tel Aviv 6701101 Israel

Bankers Bank Hapoalim Ltd.

Branch 407 Hatidhar St. 16

Raanana IA 43100 Israel

Westpac Banking Corporation

Level 4, Brookfield Place, Tower Two

123 St Georges Terrace

Perth WA 6000

ASX Code (Shares) ROO

Website www.rootssat.com

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Roots Sustainable Agricultural Technologies Ltd (referred to hereafter as the 'Company', 'Roots' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 31 December 2021.

Directors

The following persons were directors of Roots Sustainable Agricultural Technologies Ltd during the whole of the financial year and up to the date of this report, unless otherwise stated:

Sharon Devir (appointed on 19 April 2009)
Boaz Wachtel (appointed on 19 April 2009)
Adam Blumenthal (appointed on 9 November 2017)
Graeme Smith (appointed on 9 November 2017)
Dafna Shalev-Flamm (appointed 29 May 2018)
James Ellingford (appointed 24 February 2020)
Peter Hatfull (appointed 23 July 2020)

Principal activities

The principal activity of the Group during the year was the sale of root zone heating and cooling systems to greenhouse farmers and the development of irrigation systems with combined fertilization and heating/cooling roots zone management.

Review of Operations

New sale contract secured at Puerto Rican Cannabis farm:

Roots secured a new sales contract for its proprietary Root Zone Temperature Optimisation (RZTO) technology valued at A\$51,700 with Caribbean CBD Farm Inc., marking the Company's expansion into Puerto Rico. The contract consists of over 2,000 units, which will be inserted into pots located at the farm. The technology will deploy a heat pump, circulation pump and electronic panel to heat and cool the roots resulting in a greater yield. Mobile and PC applications developed by the Company will also equip farm staff with sensors, providing them real time feedback on the temperatures and functionality readings of the system.

Since the legalisation of medicinal cannabis in Puerto Rico in 2015, there has been a growing increase in patients utilising it for treatment. The territory now has 31 licenced cannabis producers, providing a large addressable market opportunity for the Company to continue to undertake business development initiatives to drive growth throughout Puerto Rico.

New small-scale RZTO system launched:

Following extensive R&D and product development initiatives, the Company launched a new, small-scale RZTO system to target additional market segments including home gardeners and non-commercial growers. The new offering is designed to assist home gardeners and others to cultivate food and other ornamentals under local weather conditions, delivering greater food security and superior cultivation quality.

The small-scale system utilises the same design and intellectual property ("IP") as the Company's existing, proprietary RZTO technology. It has an easy to operate electric heat exchange pump and can be used with up to 30 heat exchange probes for insertion into pots, grow bags or directly into soil.

It is designed to provide greater food security to gardeners and growers. By maintaining optimal root zone temperature year-round, it allows food and ornamentals to be grown through periods of extreme hot or cold weather. This provides for food production to take place locally, without the use of harmful pesticides and long-distance freighting. It also reduces greenhouse emissions and establishes a lower carbon footprint in communities.

New mid-size RZTO system offering:

The Company continued its product development with the launch of an additional new mid-size system, called the 'Super Mini'. The system also utilises the Company's proprietary RTZO technology, which optimises plant physiology for increased growth, productivity and quality by stabilising a plant's root zone temperature year around.

The 'Super Mini' system is designed for use in commercial growing operations providing growers with the ability to learn and adopt the technology to specific crops, varieties and growing conditions. As a 'plug and play' system it will reduce barriers to entry and enhance uptake, as well as allow potential distributors and dealers with the ability to test the systems advantages over the short term.

Both systems are available to buy outright or on a lease basis. Each solution can be installed by the end customer, without the need for a technician and highlights the Company's adaptive marketing approach towards COVID-19 restrictions. Roots is confident that the 'plug and play' system will reduce barriers to entry and enhance uptake.

The product launches allow Roots to offer its innovative technology in three varying sizes and target a larger segment of the addressable market. Roots is confident that the new product introductions will allow it to increase market share in the world's gardening market and the global nursery pots and planters market, which are both expected to see significant growth.

Notice of Allowance for US design patent:

The Company significantly strengthened its intellectual property portfolio during the year, receiving Notice of Allowance from the United States Patent and Trademark Office ('USPTO') for the Company's Heat Exchange Probe technology ('HEP').

The Notice of Allowance follows a stringent approval process and is the last major step in the patent application process, highlighting that an application meets all the necessary requirements for a patent to be issued. Representing a large and important market for the Company, Roots now possesses significant IP protection in several key markets including the US, Australia, China, the European Union, Turkey, Israel, United Kingdom and India.

LOI secured with established European agricultural project specialist:

Roots secured a non-binding, exclusive Letter of Intent with Serbian agriculture project developer Avital d.o.o. ('Avital') to market, sell and distribute the Company's HEP and RZTO technology in the Balkans.

Avital specialises in the initiation, integration and execution of agricultural projects by utilising their deep technological experience and a highly qualified team. Targeting the Balkan region where they boast a strong established presence, Roots will receive licensing fees for each complete system sold by Avital at a fixed percent out of the end user price.

As part of the agreement, Roots will provide an initial installation of RZTO technology at the Ivan Leposavic (Blueberry nights) farm, deploying >400 heat exchange stubs into Blueberry growing pots to accelerate growth rate and protect the crops from extreme heat and cold weather events. Success in the initial project will leave Roots well placed to expedite uptake in the region and establish a strong relationship with Avital.

Expansion into Africa through LOI with Cherry Irrigation SA:

Roots continued its international expansion with an additional LOI signed with irrigation system specialist Cherry Irrigation SA ('Cherry Irrigation'). Roots will provide exclusive marketing, sales and installation rights to Cherry Irrigation for South Africa and Namibia for a commitment period of three years conditioned on an average sale of no less than €1.0m (~A\$1.55m). Upon the sale and installation of each system, Cherry Irrigation will pay Roots a royalty at a rate to be agreed upon in the definitive agreement, anticipated in early CY22.

Both parties have agreed upon as initial purchase order of four small scale RTZO systems, which will be used as pilot installations. Roots is confident that this agreement coupled with the effectiveness of the RZTO technology will act as a catalyst for broader product uptake across the Southern African region.

The agreement marks an important milestone for Roots, with the continued international expansion and first entry into the African market. Southern Africa boasts several lucrative market verticals such as blueberry production and cannabis cultivation, which present large market opportunities for the Company.

Corporate overview

Placement to advance growth initiatives:

Roots secured firm commitments from sophisticated and professional investors to raise A\$1m (before costs), by way of a placement of 160,256,410 CDIs. The CDIs will be issued at A\$0.00624 and will rank equally with existing CDIs on issue.

Investors received one attaching option for every four Placement CDIs subscribed for and issued. The options will have a strike price of \$0.02 and an expiry date of 30 September 2023. Subject to receipt of shareholder approval, investors will also receive three attaching options for every four placement CDIs subscribed for and issued, with a strike price of \$0.0125 and an expiry date of 12 months from the date of issue.

EverBlu Capital Pty Ltd ('Everblu Capital') acted as lead manager to the Placement receiving a 6% cash fee for the total funds raised. In addition, and subject to receipt of shareholder approval, Everblu Capital will receive up to one option for every one share issued under the Placement (being up to a total of 160,256,410 options). The Broker Options will be issued on the same terms and conditions as the free attaching options issued under the Placement.

Funds from the Placement will be used to further progress the commercialisation of the Company's RZTO systems, broadening its growing international footprint, progress system installation and undertake additional marketing and business development initiatives to drive sales growth.

Dividends

There were no dividends paid or recommended during the financial year ended 31 December 2021 (2020: Nil).

Significant changes in the state of affairs

During the financial year, there were no significant changes in the state of affairs of the Group other than that referred to in the financial statements or notes thereto.

Events subsequent to the end of the period:

First revenues for 'Super Mini' RZTO booked:

The Company secured its initial sales for the Company's 'Super-Mini' RZTO system. Orders were shipped to customers and distributors in multiple international markets including Australia, Singapore and South Africa for a total amount of A\$13,000. The sales include shipments to a broad range of partners growing a diverse range of crops. This highlights the capability of the system to provide ideal growing conditions under unique and challenging environments and weather conditions and key building blocks for the Company to begin to achieve much larger commercial orders following the continued acceptance of the technology.

Roots named among five finalists for GrowingIL competition "Keeping it Cool":

The Israeli Ministry of Agriculture named Roots mong five finalists for the GrowingIL competition "Keeping it Cool". GrowingIL connects different parties in the Ag-Tech ecosystem and aims to develop the Israeli Ag-Tech ecosystem and reshape Israeli agriculture to meet emerging global food needs through the implementation of ground-breaking technologies. As a finalist for the competition, Roots will demonstrate amelioration effects of technologies on agriculture in the face of extreme weather conditions.

Expansion in Asia with first sales in Azerbaijan:

Roots secured a purchase agreement with Green Tech LLC ("Green Tech") which marks the Company's first sales into Azerbaijan, a large central Asian country with significant agricultural production primarily targeting the Russian markets. The agreement will see Green Tech purchase a 'Super Mini' RZTO system for the sum of A\$11,784 for a proof of concept on their main crop producing areas which includes tomatoes and cucumbers. Following a successful period of one or two growth cycles, Roots anticipates the POC will lead to additional larger commercial orders.

Successful RZTO installations in South Africa and Spain:

The Company successfully completed two remote installation of its 'Super Mini' system at South Africa's Cheeba Africa, Cheeba Cannabis Academy and at a commercial sweet pepper green house in Almeria, Spain. The installations were both completed remotely with the assistance of Roots local agents in the regions Cherry Irrigation and Criado y López S.L. ("Criado Y Lopez").

At the Cheeba Cannabis Academy the installation was carried our under an equal split cost (\$2,500 between the Academy and ROOTS). The commercial terms in Spain remain the same as the installation in South Africa with an equal split cost between Criado Y Lopez and ROOTS (\$3,500 each). Since installation all parties have subsequently reported the system is in operation and performing well.

No other matter or circumstance has arisen since 31 December 2021 that has significantly affected, or may significantly affect the entity's operations, the results of those operations, or the entity's state of affairs in future financial years.

Likely developments and expected results of operations

The company will work to expand its commercial activity internationally. An emphasis will be on the Cannabis sector.

Information on Directors

Name: Mr Boaz Wachtel

Title: Executive Chairman and CEO

Qualifications: Masters in Management and Marketing

Experience and expertise: Mr. Wachtel is the Co-Founder and Executive Director of Roots. Mr. Wachtel is the

inventor of irrigation by condensation (NASA Tech Brief magazine- Technologies of the Month) and root zone heating and cooling – ROOTS's core technologies. He has published 25 publications 6peciali on water and he is a frequent lecturer on agricultural technology, Middle East water issues and sustainability. He is a former assistant army attaché to the Israeli Embassy in Washington DC and has lectured at the UN conflict resolution conference. Mr Wachtel holds a Masters in Management

and Marketing from the University of Maryland.

Other current directorships: Creso Pharma Limited

Former directorships (last 3 years): Nil

Special responsibilities: Chairman, CEO Interests in shares: 5,376,777 CDIs

Interests in options: 1,850,510 Unlisted Options

250,000 Listed Options

Contractual rights to shares: 13,500,000 Performance Rights

Name: Mr Sharon Devir

Title: Executive Director, Business Development

Qualifications: BSc, MSc, PHD

Experience and expertise: Dr Devir is a Co-Founder and Chief Executive Officer of Roots. He previously

cofounded Salicrop, an abiotic stress seed treatment technology as well as Rimonim, an Agri-Tech fund. Dr Devir was the former Chief Executive Officer of NGT, a technology incubator which sold a company Flourinex to Colgate for US\$100 million. He was also the Former Chief Scientific Officer of AFIMILK dairy management systems and he has lectured at The Hebrew University, Israel on behalf of the Agriculture Faculty. Dr Devir's achievements led to being awarded the "Man of the Year" award by Israeli TV Channel 2 and the Daily "Yediot Acharonot" newspaper

for his Unique Social Contribution.

Other current directorships: Salicrop, SkyX, Rimonim Agro Management

Former directorships (last 3 years): Nil

Special responsibilities: Business Development

Interests in shares: 2,959,564 CDIs

Interests in options: 2,430,490 Unlisted Options 100,000 Listed Options

Contractual rights to shares: 13,500,000 Performance Rights

Name: Mr Adam Blumenthal Title: Non-Executive Director

Qualifications: Bachelor of Commerce, a Masters of International

Relations and a Masters of Business Administration

Experience and expertise: Mr Blumenthal has 10 years' experience in investment banking and corporate

finance. He has deep exposure to Australian and international markets, having provided capital raising and financing solutions to an extensive number of unlisted and listed companies. Mr Blumenthal has played a lead role in advising and supporting multiple organisations across a broad spectrum of industries. Using his experience and extensive network of international contacts to provide corporate advisory and capital markets input, he has successfully brought to market several companies and is actively involved in mining, cyber security, agricultural technology, medicinal cannabis, pharmaceutical and information technology sectors. Mr Blumenthal is a shareholder of EverBlu, the Lead Manager to the Offer and, on 23

August 2017, was appointed as the Chairman on EverBlu.

Other current directorships: Creso Pharma Limited

Burrabulla Corporation Limited

Former directorships (last 3 years): Nil

Contractual rights to shares:

Interests in shares: 43,638,831 CDIs

Interests in options: 4,535,650 Listed Options

1,833,333 Unquoted Options 4,200,000 Performance Rights

Name: Mr Graeme Smith

Title: Independent Director and Non-Executive Director

Qualifications: Certified Practicing Agriculturist (CPAG)

Experience and expertise: Mr Smith is a Melbourne-based, world agriculture and horticulture expert, consultant

and lecturer. Mr Smith is a Certified Practicing Agriculturist (CPAG), from the Australian Institute Agricultural Science and Technology. Graeme Smith Consulting has (beginning with Hydroponic Designs Pty Ltd), delivered over 40 protected cropping projects around Australia since 1995. These projects have largely delivered modern greenhouse food production systems ranging from 400m2 to 160,000m2 in poly tunnels through to modern glasshouses. Most of Mr Smith's food production projects involved full return on, system design, costings, project management, as

well as commissioning and ongoing crop advisory services.

Other current directorships: 288,750
Former directorships (last 3 years): Nil
Interests in shares: Nil

Interests in shares:
Interests in options:
Contractual rights to shares:
Nil

Name: Ms Dafna Shalev-Flamm (appointed 29 May 2018)
Title: Independent Director and Non-Executive Director

Qualifications: Certified Public Accountant, MBA

Experience and expertise: Ms Shalev-Flamm was an experienced Chief Financial Officer and Director with

extensive experience in operational management, accounting and finance, capital

management and corporate governance.

Other current directorships: Plasson Industries Ltd

MTI Computers Software Services Ltd

Dolinom I to

Former directorships (last 3 years): Poliram Ltd

Special responsibilities: Chair of the Audit and Remuneration Committees

Interests in shares: 934,375
Interests in options: Nil
Contractual rights to shares: Nil

Name: Dr James Ellingford (appointed 24 February 2020) Independent Director and Non-Executive Director Title:

Qualifications: MBA. PG (Corp Mgmt). D.Mgt

Dr Ellingford previously served as International President of a multi-billion dollar Experience and expertise:

NASDAQ software business Take-Two Interactive Software with its headquarters in Geneva and New York. He has vast international experience in the software industry and has close ties with financial institutions and governments throughout the world. Dr Ellingford has had ample experience over the last several years in the Cannabis space as well as living for a period in West Coast of USA. This will serve Roots very well, given Roots is currently strengthening its focus on the Cannabis space in California. He is considered an expert in the areas of collaboration of media and digital assets, data sharing and corporate communications to enable workflow acceleration and has close ties with large US based corporates who dominate this space. Dr Ellingford holds a Postgraduate in Corporate Management, Master's in Business Administration and a Doctorate in Management. Dr Ellingford has lectured MBA students in Corporate Governance, ethics and marketing at a leading Sydney

University which are areas he has a keen interest in.

Minrex Resources Limited Other current directorships:

Creso Pharma Limited Esense-Lab Limited

Former directorships (last 3 years): Victory Mines Limited

Paterson Resources Limited

Manalto Limited

Burrabulla Corporation Limited

Special responsibilities: Nil Interests in shares: Nil Interests in options: Nil Contractual rights to shares: Nil

Mr Peter Hatfull (appointed 23 July 2020) Name:

Title: Independent Director and Non-Executive Director

Qualifications: Qualified as a Chartered Accountant in England and Wales

Peter has over 40 years' experience in a range of Board and senior executive Experience and expertise:

positions with Australian and international companies. He has an extensive skill-set

in the areas of business optimisation, capital raising and Group restructuring.

Peter is a professional Director and is currently the independent Chairman of several listed and unlisted companies. Peter specializes in corporate governance and strategic planning and has held senior financial and board positions in Australia, Africa and the UK. Peter graduated as a Chartered Accountant in the United Kingdom where he worked for Coopers and Lybrand (now PriceWaterhouseCoopers), and subsequently moved to Africa, where he spent 8 years in Malawi prior to moving to

Australia.

Other current directorships: Raphael Resources Limited

eSense Lab Ltd

Former directorships (last 3 years): Affinity Energy and Health Ltd

Special responsibilities: Nil Interests in shares: Nil Interests in options: Nil Contractual rights to shares: Nil

Company secretary

Ms Sarah Smith

Ms Smith specializes in corporate advisory, company secretarial and financial management services. Ms Smith's experience includes company secretarial and financial management services for ASX listed companies, capital raisings and IPOs, due diligence reviews and ASX and ASIC compliance. Ms Smith is a Chartered Accountant and has acted as the Company Secretary for a number of ASX listed companies.

Meetings of directors

The number of meetings of the company's Board of Directors ('the Board') and of each Board committee held during the year ended 31 December 2021, and the number of meetings attended by each director were:

	Directors' Meetings			Audit Committee Meetings		Remuneration Committee Meetings	
	Attended	Held	Attended	Held	Attended	Held	
Boaz Wachtel	2	2	-	-	-	-	
Sharon Devir	2	2	-	-	-	-	
Adam Blumenthal	2	2	-	-	-	-	
Graeme Smith	2	2	2	2	1	1	
Dafna Shalev-Flamm	2	2	2	2	1	1	
James Ellingford	2	2	2	2	1	1	
Peter Hatfull	2	2	-	-	-	-	

Shares under option

At the date of this report, the unissued ordinary shares under option are as follows:

Grant date	Expiry date	Exercise price	Number under option
29 November 2017	30 November 2022	AUD \$0.01	1,655,000
25 July 2019	17 June 2024	AUD\$0.01	602,500
24 July 2019	24 July 2022	AUD \$0.12	5,408,592
17 September 2019	24 July 2022	AUD \$0.12	8,423,810
23 December 2019	24 July 2022	AUD \$0.12	6,333,350
15 October 2021	24 July 2022	AUD \$0.12	1,000,000
15 October 2021	15 October 2026	AUD \$0.01	4,833,333
15 October 2021	30 September 2023	AUD \$0.02	40,064,103

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the company or of any other body corporate.

At the date of this report, the number of performance rights on issue was as follows:

Grant date	Class	Expiry date	Number of rights issued
11 September 2019	Class E	17 September 2023	4,400,000
11 September 2019	Class F	17 September 2022	4,400,000
11 September 2019	Class G	17 March 2022	4,400,000
18 October 2021	Class H	18 October 2024	6,000,000
18 October 2021	Class I	18 October 2024	6,000,000
18 October 2021	Class J	18 October 2024	6,000,000
			31,200,000

Class	Milestone
Class E Performance Rights	The Class E Performance Rights will be able to be converted into a CDI by a Holder, upon the Company:
	(a) Acquiring a business in the agricultural and/or cannabis or hemp sector which contributes to the Company's gross revenue by a minimum of 10% within 12 months from acquisition of the relevant business (Acquisition); and following completion of the Acquisition, the Company's CDIs trading at a 20-day VWAP of A\$0.12 or more.
Class F Performance Rights	The Class F Performance Rights will be able to be converted into a CDI by a Holder upon the Company recording gross revenue of \$500,000 as a result of:
	(a) Expansion into the US cannabis market; and/or sales in Israel.

Class G Performance Rights The Class G Performance Rights will be able to be converted into a CDI by a Holder

upon the Company installing:

(a) four (4) RZTO systems for cannabis or hemp clients globally; and

(b) two (2) additional RZTO system installations in the Asian market.

Class H Performance Rights The Class H Performance Rights will be able to be converted into a CDI by a Holder within 36 months of the date of issue, upon the Company:

(a) executing a joint venture agreement with a company with a synergic technology; and

(b) recording gross sales of at least AUD\$100,000 pursuant to the joint venture with the first 12 months of the date of execution of the JV agreement.

Class I Performance Rights The Class I Performance Rights will be able to be converted into a CDI by a Holder upon the Company:

(a) recording gross sales of AUD\$500,000 (excluding any sales that is utilized for the purposes of satisfying the Class H Performance Rights milestone) within 18 months of the date of issue of the performance rights.

Class J Performance Rights The Class J Performance Rights will be able to be converted into a CDI by a Holder upon the Company:

(b) recording gross sales of AUD\$300,000 as a result of signing letters of intent or definitive dealership agreements in at least three new territories within 24 months of the date of issue of the performance rights.

The performance rights will vest and become capable of exercise into ordinary shares in the Company upon the satisfaction of vesting conditions as disclosed above.

Shares issued on the exercise of options

At the date of this report, no shares were issued on the exercise of options.

Indemnifying Officers

The Company indemnifies each of its Directors and Officers. The Company indemnifies each Director or Officer to the maximum extent permitted by the Israeli Companies Law, 5759-1999 from liability to third parties, except where the liability arises out of conduct involving lack of good faith, and in defending legal and administrative proceedings and applications for such proceedings.

The Company must use its best endeavours to insure a Director or Officer against any liability, which does not arise out of conduct constituting a willful breach of duty or a contravention of the Israeli Companies Law, 5759-1999. The Company must also use its best endeavours to insure a Director or Officer against liability for costs and expenses incurred in defending proceedings whether civil or criminal.

Insurance Premiums

During the year, the Company paid insurance premiums to insure Directors and Officers against certain liabilities arising out of their conduct while acting as an officer of the Group. Under the terms and conditions of the insurance contract, the nature of the liabilities insured against and the premium paid cannot be disclosed.

Indemnity and insurance of auditor

The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the company or any related entity against a liability incurred by the auditor.

During the financial year, the company has not paid a premium in respect of a contract to insure the auditor of the company or any related entity.

Proceedings on behalf of the company

No person has applied for leave of Court to bring proceedings on behalf of the Company or intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the company for all or any part of those proceedings.

The Company was not a party to any such proceedings during the year.

Non-audit services

During the year, BDO Israel, the Company's auditor, did not provide any services other than their statutory audits.

In the event that non-audit services are provided by BDO Israel, the Board has established certain procedures to ensure that the provision of non-audit services are compatible with, and not compromise the auditor independence. These procedures include:

- all non-audit services will be subject to the corporate governance procedures adopted by the Company and will be reviewed by the Board to ensure they do not impact the integrity and objectivity of the auditor; and
- ensuring non-audit services do not involve reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the Company, acting as an advocate for the Company or jointly sharing risks and rewards.

Corporations Act 2001

As a foreign company registered in Australia, the Company will not be subject to Chapters 6A, 6B and 6C of the Corporations Act dealing with the acquisition of shares (e.g. substantial holders and takeovers).

Under the Israeli Companies Law there are restrictions on acquisition of shares, requiring a tender offer for acquisition of public Company shares resulting in a holding of 25% or more voting rights of the Company. In addition, under the Companies Law, a person may not purchase shares of a public company if, following the purchase of shares, the purchaser would hold more than 90% of the company's shares, unless the purchaser makes a tender offer to purchase all of the target company's shares. Otherwise, the acquisition of the company's securities generally not restricted by the company's articles of association or the laws of Israel, except that Israeli law prohibits the ownership of securities by nationals of certain countries that are, or have been, in a state of war with Israel.

Environmental Regulations

In the normal course of business, there are no environmental regulations or requirements that the Company is subject to.

This report is made in accordance with a resolution of directors.

On behalf of the directors

Boaz Wachtel
Executive Chairman

28 February 2022 Beit-Halevi

ASX ADDITIONAL INFORMATION

1. SHAREHOLDINGS

The Company has ordinary shares on issue. The Company's ordinary shares traded on the ASX are traded as Chess Depository Interests ('CDI's') under the code ROO. Each CDI has a beneficial interest in a share.

The issued capital of the Company as at 24 February 2022 is 749,632,688. All issued CDI's carry one vote per share. The number of holders of CDI's is 3,563.

The number of Listed Options on issue as at 24 February 2022 is 21,165,752 (exercisable at AUD\$0.12 on or before 24 July 2022).

The Company as at 24 February 2022 has on issue the following unlisted securities:

- 47,154,936 unlisted options; and
- 31,200,000 performance rights.

Unquoted Options

Grant date	Expiry date	Exercise price	Number under option
29 November 2017	30 November 2022	AUD \$0.01	1,655,000
25 July 2019	17 June 2024	AUD\$0.01	602,500
24 July 2019	24 July 2022	AUD \$0.12	5,408,592
17 September 2019	24 July 2022	AUD \$0.12	8,423,810
23 December 2019	24 July 2022	AUD \$0.12	6,333,350
15 October 2021	24 July 2022	AUD \$0.12	1,000,000
15 October 2021	15 October 2026	AUD \$0.01	4,833,333
15 October 2021	30 September 2023	AUD \$0.02	40,064,103

Performance Rights

Grant date	Class	Expiry date	Number of rights issued
11 September 2019	Class E	17 September 2023	4,400,000
11 September 2019	Class F	17 September 2022	4,400,000
11 September 2019	Class G	17 March 2022	4,400,000
18 October 2021	Class H	18 October 2024	6,000,000
18 October 2021	Class I	18 October 2024	6,000,000
18 October 2021	Class J	18 October 2024	6,000,000

2. DISTRIBUTION OF EQUITY SECURITIES (SHAREHOLDERS AND CDI HOLDERS)

Range	Total holders	Units	% of Issued Capital
1 - 1,000	70	22,575	0.00%
1,001 - 5,000	436	1,135,855	0.15%
5,001 - 10,000	236	1,942,262	0.26%
10,001 - 100,000	1,855	82,340,624	10.98%
Above 100,000	966	664,191,372	88.60%
Т	otal 3,563	749,632,688	100.00%

There are 2,597 number of investors holding a less than marketable parcel of 85,441,316 ROO shares based on a share price of A\$0.005 at 24 February 2022.

3. TOP TWENTY LARGEST SHAREHOLDERS AS AT 24 FEBRUARY 2022

	Holder Name	Number Held	Percentage
1	JAMBER INVESTMENTS PTY LTD <the a="" amber="" c="" fam="" schwarz=""></the>	79,613,522	10.62%
2	ATLANTIC CAPITAL HOLDINGS PTY LTD <atlantic a="" c="" capital=""></atlantic>	42,367,533	5.65%
3	ANANDI INVESTMENTS PTY LTD <patel a="" c="" family=""></patel>	27,344,642	3.65%
4	CHIFLEY PORTFOLIOS PTY LTD	16,025,641	2.14%
5	MR MARK ANDREW TKOCZ	8,807,424	1.17%
6	MR GREG HUGH PRIESTLEY	8,200,000	1.09%
7	YUCAJA PTY LTD <the a="" c="" family="" yoegiar=""></the>	7,730,857	1.03%
8	CITICORP NOMINEES PTY LIMITED	6,256,142	0.83%
9	MR MICHAEL ERNEST GRANATA <the a="" c="" family="" granata=""></the>	5,500,000	0.73%
10	BNP PARIBAS NOMINEES PTY LTD SIX SIS LTD <drp a="" c=""></drp>	5,355,800	0.71%
11	BOAZ WACHTEL	5,298,777	0.71%
12	MISS MELODY AN	4,601,000	0.61%
13	P & L LOWMAN PTY LTD <p &="" a="" c="" fund="" l="" lowman="" super=""></p>	4,450,000	0.59%
14	MR BIN XU	4,400,000	0.59%
15	MR HAOCHEN HU	4,000,000	0.53%
16	CS FOURTH NOMINEES PTY LIMITED < HSBC CUST NOM AU LTD 11 A/C>	3,729,360	0.50%
17	MR DAVID ALEXANDER KENNEDY & MRS YUJIN JEONG	3,701,111	0.49%
18	MR HIMANSHU PATEL	3,419,932	0.46%
19	DR VIPUL BANSAL	3,398,264	0.45%
20	GREENWOOD TRADING FUND PTY LTD	3,221,721	0.43%
Total	: Top 20 holders	247,421,726	33.01%
Total	: Issued Capital	749,632,688	100.00%

4. TOP TWENTY LARGEST LISTED OPTIONHOLDERS AS AT 24 FEBRUARY 2022

	Holder Name	Number Held	Percentage
1	MS YASMIN ELIZABETH ILIC	2,333,783	11.03%
2	JAMBER INVESTMENTS PTY LTD	1,785,353	8.44%
	<the a="" amber="" c="" fam="" schwarz=""></the>		
3	AUSTRALIAN SHARE NOMINEES PTY LIMITED	1,450,000	6.85%
	<australasian ac="" holding=""></australasian>		
3	ANGLO AUSTRALASIA HOLDINGS PTY LTD	1,450,000	6.85%
	<anglo a="" australasia="" c=""></anglo>		
4	ATLANTIC CAPITAL HOLDINGS PTY LTD	1,000,000	4.72%
	<atlantic a="" c="" capital=""></atlantic>		
5	MRS SIXIA XUE	986,606	4.66%
6	M & K KORKIDAS PTY LTD	932,620	4.41%
	<m&k a="" c="" fund="" korkidas="" l="" p="" s=""></m&k>		
7	MR RAMIN VAHDANI	750,000	3.54%
8	M & K KORKIDAS PTY LTD	624,889	2.95%
	<m &="" a="" c="" k="" korkidas="" ltd="" pty=""></m>		
9	MR JENS ROESTEL	550,000	2.60%
10	MS LISA ASHE	500,000	2.36%
10	MISS NUTCHA WONGINPHOR	500,000	2.36%
10	PETARD PTY LTD	500,000	2.36%
11	ADAM BLUMENTHAL	458,334	2.17%
12	MR ALAN DENNIS HAZELL	351,500	1.66%
13	PARRY CAPITAL MANAGEMENT LIMITED	333,333	1.57%
	<parry a="" c="" fund="" sit="" sp="" spec=""></parry>		
14	PARRY CAPITAL MANAGEMENT LIMITED	265,879	1.26%
	<special a="" c="" situations=""></special>		
15	CAREEN HOLDINGS PTY LTD	258,585	1.22%
	<peter a="" c="" lewin="" retirement=""></peter>		
16	MR BOAZ WACHTEL	250,000	1.18%
16	MR THOMAS VAN KANN &	250,000	1.18%
	MRS NATALIA VAN KANN		
	<tn a="" c="" f="" kann="" s="" van=""></tn>		
17	MR PAUL SIEGLE &	237,749	1.12%
	MRS MECHELLE SIEGLE		
	<siegs a="" c="" fund="" super=""></siegs>		
18	MRS CAROLYN KATZ	225,000	1.06%
19	MR COLIN RICHARD KORN	222,378	1.05%
20	SOLEVU PTY LTD	216,667	1.02%
	<rt a="" c="" fund="" lin="" super=""></rt>		
Total:	Top 20 holders	16,432,676	77.64%
Total:	Listed Options @ \$0.12; expiry 24/07/2022	21,165,752	100.00%
			· · · · · · · · · · · · · · · · · · ·

5. VOTING RIGHTS

Ordinary shareholders have the right to one vote at a meeting of Shareholders of the Company or a Resolutions of Shareholders.

CDI Holders do not hold the right to vote at meetings of the Company and if they wish to take a vote, they must direct the CHESS Depositary Nominees (CDN) on how to vote in advance of the applicable meeting, provided that both Shareholders and CDI Holders are able to attend meetings.

6. SUBSTANTIAL SHAREHOLDERS AS AT 24 FEBRUARY 2022

	Holder Name	Number Held	Percentage
1	JAMBER INVESTMENTS PTY LTD <the a="" amber="" c="" fam="" schwarz=""></the>	79,613,522	10.62%
2	ATLANTIC CAPITAL HOLDINGS PTY LTD <atlantic a="" c="" capital=""></atlantic>	42,367,533	5.65%

7. RESTRICTED SECURITIES SUBJECT TO ESCROW

There are no shares on issue that are subject to voluntary escrow restrictions or mandatory escrow restriction under ASX Listing Rules Chapter 9.

8. ON-MARKET BUY BACK

There is current no on-market buyback program for any Roots listed securities.

ARBN 619 754 540

Preliminary Final Report For the year ended December 31, 2021

December 31, 2021

TABLE OF CONTENTS

	Page
Statements of Financial Position	3-4
Statements of Comprehensive Loss	5
Statements of Changes in Equity (deficit)	6-7
Statements of Cash flows	8
Notes to the Financial Statements	9-36

All amounts are stated in U.S. dollars (\$)

ARBN 619 754 540

Statements of Financial Position

		As at Decei	mber 31,
	-	2021	2020
	Note	\$'000	\$'000
ASSETS			
Current Assets			
Cash and cash equivalents		1,424	3,067
Restricted cash	6.B	42	84
Trade receivables		62	126
Other accounts receivables	4	249	191
Total Current Assets	-	1,777	3,468
Non-Current Assets			
Property and equipment, net	<u>-</u>	46	56
Total Non-Current Assets	-	46	56
TOTAL ASSETS	-	1,823	3,524

ARBN 619 754 540

Statements of Financial Position

		As at December 31,	
	_	2021	2020
	Note	\$'000	\$'000
LIABILITIES AND EQUITY			
Current Liabilities			
Trade payables		28	86
Other account payables	5	458	568
Derivative liability – warrants	_	189	-
Total Current Liabilities	=	675	654
Non-Current Liabilities			
Derivative liability – warrants		-	76
Governmental liabilities on grants received	6.C	368	356
Total Non-Current Liabilities	-	368	432
Shareholder's equity (deficit)			
Equity attributable to owners of the parent Share capital	7	18,290	17,553
Warrants	•	164	164
Foreign currency translation reserve		(234)	(158)
Accumulated losses	_	(17,440)	(15,121)
Total equity (deficit)	_	780	2,438
TOTAL LIABILITIES AND EQUITY	=	1,823	3,524

ARBN 619 754 540

Statements of Comprehensive loss

		For the year ended December 31,		
	Note	2021 \$'000	2020 \$'000	
Revenues	10	187	107	
Cost of revenues		117	94	
Gross profit		70	13	
Research and development expenses, net	11	490	349	
Marketing, distribution and business development expenses	12	605	751	
General and administrative expenses	13	1,156	1,909	
Loss from operations		2,181	2,996	
Finance expense	14	206	251	
Finance income	14	68	45	
Loss before income tax		2,319	3,202	
Income tax	15	<u>-</u>		
Net loss		2,319	3,202	
Other comprehensive loss				
Items that will not be reclassified to profit or loss:				
Translation adjustment to the presentation currency		76	(19)	
Total comprehensive loss	-	2,395	3,183	
Loss per share				
Basic and diluted loss per share (\$)	7,9	(0.006)	(0.014)	

ARBN 619 754 540

Statements of Changes in Equity (deficit)

For the year ended December 31, 2021:

				Foreign		
		Share		Currency Translation	Accumulated	Total
	Note	Capital	Warrants	Reserve	Deficit	Equity
		\$'000	\$'000	\$'000	\$'000	\$'000
Balance at January 1, 2021		17,553	164	(158)	(15,121)	2,438
Changes during the period:						
Comprehensive loss:						
Loss for the period		-	-	-	(2,319)	(2,319)
Other comprehensive loss:						
Translation differences		-	-	(76)	-	(76)
Total comprehensive loss for the period	[-	-	(76)	(2,319)	(2,395)
Issuance of shares, net	7	370	-	-	-	370
Issuance of Performance rights	8(b)	120	-	-	-	120
Issuance of shares to suppliers in lieu o	f					
cash payment		39	-	-	-	39
Share-based compensation	8(a)	208		_		208
Balance as of December 31, 2021		18,290	164	(234)	(17,440)	780

ARBN 619 754 540

Statements of Changes in Equity (deficit)

For the year ended December 31, 2020:

	Note	Share Capital \$'000	Warrants \$'000	Foreign Currency Translation Reserve \$'000	Accumulated Deficit \$'000	Total Equity \$'000
Balance at January 1, 2020		11,468	164	(177)	(11,919)	(464)
Changes during the period:						
Comprehensive loss:						
Loss for the period		-	-	-	(3,202)	(3,202)
Other comprehensive loss:						
Translation differences		-		19		19
Total comprehensive loss for the period		-	-	19	(3,202)	(3,183)
Issuance of shares, net	7	4,642	-	-	-	4,642
Conversion of convertible notes to shares		106	-	-	-	106
Conversion of short term loans to shares		318	-	-	-	318
Issuance of shares to suppliers in lieu of cash payment	^f 7	422	-	-	-	422
Share-based compensation		597		-		597
Balance as of December 31, 2020		17,553	164	(158)	(15,121)	2,438

ARBN 619 754 540

Statements of Cash Flows

	Note	For the year ended December 31,	
	_	2021	2020
	_	\$'000	\$'000
Cash Flows from Operating Activities:			
Net loss for the year		(2,319)	(3,202)
Adjustments to reconcile net loss to net cash provided by operating activities:			
Depreciation		17	16
Share-based compensation expenses		155	226
Changes in fair value of derivatives		(60)	39
Changes in fair value of convertible notes		-	(72)
Change in liability for grants received from the IIA		(124)	(41)
Interest on liability for grants received from the IIA		93	89
Finance expense, net		(1)	15
Interest on short term loans		-	111
Change in trade receivable		65	33
Change in other receivable		(79)	(30)
Change in trade payable		(60)	342
Change in other payable		(113)	11
Net cash used in operating activities		(2,426)	(2,463)
Cash Flows From Investing Activities:			
Purchase of property and equipment		(5)	(13)
Change in restricted cash		45	(39)
Net cash provided by (used in) investing activities		40	(52)
Cash Flows From Financing Activities:			
Receipt of short term loans		_	183
Net proceeds from issuance of shares		-	5,013
Net proceeds from issuance of unit of securities	7	716	-
Net cash provided by financing activities		716	5,196
Increase (decrease) in cash and cash equivalents		(1,670)	2,681
Translation differences on cash and cash equivalents		27	45
Cash and cash equivalents at beginning of the year	-	3,067	341
Cash and cash equivalents at the end of the year		1,424	3,067

ARBN 619 754 540

Notes to the Financial Statements

NOTE 1 - GENERAL:

- A. Roots Sustainable Agricultural Technologies Ltd (the "Company") was incorporated in Israel on 20 April 2009 but commenced its operations in November 2012. The Company is listed, and its shares are publicly traded on the Australian Securities Exchange ("ASX").
 - Roots is an agriculture technology company focused on developing, producing and commercializing precision agriculture technologies that address difficult weather conditions, improve crop yields and provide water for irrigation in a cost effective and environmentally sustainable manner.
 - The formal address of the Company is Hamezach 1 Str. Kefar Vitkin, Israel.
- B. The company is in its commercialization stage and does not generate significant revenue in this stage and financed its operation up to date mainly by issuance of shares. As of December 31, 2021 the Company has incurred negative cash from operation of 2,426 USD and net losses of USD 2,319 thousand for the current year. As a result of these matters, there is a material uncertainty that may cast significant doubt on the entity's ability to continue as a going concern. The financial report does not include adjustments relating to the recoverability or classification of the recorded assets nor to the amounts or classification of liabilities that might be necessary should the company not be able to continue as a going concern.
 - The directors believe that the company will be able to pay its debts when they fall due, and to fund near term anticipated activities based on proceed from future fund raising in addition to revenues backlog. The Directors are satisfied that it is appropriate to prepare the financial statements on a going concern basis on the basis that the above can be reasonably expected to be accomplished.
- C. The world Health Organization declared coronavirus and COVID-19 a global health emergency on 30 January 2020. Since then, A Layout has experienced significant disruption to its operations in the following respects:
 - The closure of many retail locations due to local governments mandating that shopping centers and other 'non-essential' businesses cease normal operations;
 - Disruptions in the supply of inventory from major suppliers;
 - Decreased demand for certain products as a consequence of social distancing requirements and recommendations; and
 - Significant uncertainty concerning when government lockdowns will be lifted, social distancing requirements will be eased and the long-term effects of the pandemic on the demand for A Layout's primary products.

The significant events and transactions that have occurred since 31 December 2020 relate to the effects of the global pandemic on A Layout's interim consolidated financial statements for the year ended 31 December 2021 and are summarized as follows.

ARBN 619 754 540

Notes to the Financial Statements

NOTE 1 – GENERAL (CONT.):

The COVID-19 had no material effect on Roots financial position, however the effects on the activity were as follows:

- 1. The company intentionally reduced its work force to adopt to the new situation and decrease in activity, which resulted in reduced monthly expenditure.
- 2. Slowed down the overall business activity.
- 3. Shift in focus from international market to domestic market.
- 4. Developed strategic alliances in Israel to boost sales and streamline operation.
- 5. Launched North America S&M marketing campaign to prepare to market opening.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:

The following accounting policies have been applied consistently in the financial statements for all periods presented, unless otherwise stated.

A. Basis of preparation:

The principal accounting policies adopted in the preparation of the financial statements are set out below. The policies have been consistently applied to all the years presented, unless otherwise stated.

These financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS). The financial statements have been prepared under the historical cost convention unless otherwise stated below.

B. Estimates and assumptions:

The preparation of the financial statements requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported amounts of assets, liabilities, revenue and expenses. These estimates and underlying assumptions are reviewed regularly. Changes in accounting estimates are reported in the period of the change in estimate.

The key assumptions made in the financial statements concerning uncertainties at the end of the reporting period and the critical estimates used by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed in Note 3.

C. Functional and reporting currency:

The majority of the Company's costs are incurred in New Israeli Shekel (hereafter "NIS"). Thus, the functional currency of the Company is NIS.

The financial statements are presented in United States Dollars, which provides relevant information for the majority of investors and users of the financial statements. All values are rounded to the nearest dollar unless otherwise stated.

Assets and liabilities are translated at the closing rate at each reporting date. Profit or loss items are translated at average exchange rates for all periods presented. The resulting translation differences are recognized in other comprehensive loss.

D. Foreign currency transactions:

Transactions denominated in foreign currency (other than the functional currency) are recognized on initial recognition at the exchange rate as of the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate as of that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate as of the date of the transaction.

E. Governmental liabilities on grants received:

Grants received from the IIA for Israel Innovation Authority (henceforth "IIA") as support for a research and development projects include an obligation to pay back royalties conditional on future sales arising from the project. Grants received from the IIA are accounted for as forgivable loans, accordingly, when the liability for the loan is first recognized, it is measured at fair value using a discount rate that reflects a market rate of interest at the date of receiving the grant, unless there is reasonable assurance that the company will meet the conditions for the forgiveness of the loan, then recognized as a government grant. The difference between the amount of the grants received and the fair value of the liability is accounted for upon recognition of the liability as a grant and recognized in profit or loss as a reduction of research and development expenses. After initial recognition, the liability is measured at amortized cost using the effective interest method. Changes in the projected cash flows are discounted using the original effective interest and recognized in profit or loss. At the end of each reporting period, the company evaluates, based on its best estimate of future sales, whether there is reasonable assurance that the liability recognized, will not be repaid. If there is such reasonable assurance, the appropriate amount of the liability is derecognized and recognized in profit or loss as an adjustment of research and development expenses.

Changes in the liability resulting from a change in future royalty payments are recognized in research and development expenses.

F. Cash equivalents:

Cash equivalents are considered by the Company to be highly-liquid investments, including, inter alia, short-term deposits with banks and the maturity of which do not exceed three months at the time of deposit and which are not restricted.

G. Restricted cash:

Restricted cash is considered by the Company to be deposits with banks which are used mainly as a security for guarantees provided against payable payments in advance.

H. Deferred taxation:

Deferred tax asset or liability is recognized where the carrying amount of an asset or liability in the statement of financial position differs from its tax base. Recognition of deferred tax asset is restricted to

those instances where it is probable that such difference can be utilized. As of December 31, 2021 and 2020, since it is not probable that taxable profit will be available in the foreseen future therefore no deferred tax assets recognized.

I. Impairment of non-financial assets:

Other non-financial assets are subject to impairment tests whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Where the carrying value of the non-financial asset exceeds its recoverable amount (i.e. the higher of value in use and fair value less costs to dispose), the asset is written down and impairment charge is recognized accordingly.

Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset's cash-generating unit (i.e. the smallest Company of assets to which the asset belongs that generates cash inflow that are largely independent of cash inflows from other assets).

During the years 2021 and 2020 no impairment charges of non-financial assets were recognized.

J. Fair value measurement:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- 1. In the principal market for the asset or liability, or
- 2. In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible to by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient

data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

Classification of fair value hierarchy

The financial instruments presented in the statement of financial position at fair value are grouped into classes with similar characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value:

- Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 Inputs other than quoted prices included within Level 1 that are observable either directly or indirectly.
- Level 3 Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).

K. Financial instruments:

1. Financial assets:

The Company classifies its financial assets based on the business model for managing the financial asset and its contractual cash flow characteristics. The Company's accounting policy for the relevant category is as follows:

Amortized cost

These assets arise principally from bank deposits, restricted cash, provision of goods and services to customers (eg trade receivables), but also incorporate other types of financial assets where the objective is to hold these assets in order to collect contractual cash flows and the contractual cash flows are solely payments of principal and interest. They are initially recognized at fair value plus transaction costs that are directly attributable to their acquisition or issue, and are subsequently carried at amortized cost using the effective interest rate method, less provision for impairment.

The Company measures provision of expected credit loss for financial assets at amortized cost, For December 31, 2021 and 2020, the provision is not material.

2. Financial Liabilities:

The Company classifies its financial liabilities into one of two categories:

Amortized cost

These liabilities include Governmental liabilities on grants received and trade receivables, initially recognized at fair value less transaction costs that are directly attributable to the issue of the instrument, and are subsequently carried at amortized cost using the effective interest rate method.

Fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities designated upon initial recognition as at fair value through profit or loss (convertible notes) and derivatives (Derivative liability – warrants).

Financial liabilities at fair value through profit or loss are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss. The amount of change in the fair value of the financial liability that is attributable to changes in the credit risk of that liability is recognized in other comprehensive income, unless the recognition of the effects of changes in the liability's credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss.

3. Derecognition:

Financial assets

The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the rights to receive the contractual cash flows.

Financial Liabilities

The Company derecognizes a financial liability when its contractual obligations are discharged or Cancelled, or expire.

Extinguishing Financial Liabilities with Equity Instruments

When the Company issues equity instruments to a creditor to extinguish all or part of a financial liability, the Company derecognizes the financial liability fully or partly. The Company measures the equity instruments issued to the creditor at their fair value (or, if fair value is not reliably determinable, at the fair value of the liability extinguished). The Company recognizes in profit or loss any difference between the carrying amount of the financial liability (or part) extinguished and the measurement of the equity instruments issued.

4. Issue of a unit of securities:

The issue of a unit of securities involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial derivatives instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.

5. Derivative liability - Warrants:

Warrants that are denominated in a currency other than the functional currency of the Company are considered a derivative liability and are classified as financial liabilities at fair value through profit or loss.

L. Provisions:

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material). When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

M. Revenue from contracts with customers

Revenue from contracts with customers is recognized when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services

Revenues from Construction Contracts

The Company design and execute installation projects in the field of agriculture. The Company recognizes income from construction contracts over time, since the Company's performance creates an asset that the customer controls as the asset is created. Revenues are recognize by the input methods.

The Company recognizes revenue based on the cost incurred to date. It is determined by dividing actual completion costs incurred to date by the total completion costs anticipated.

When a loss from a contract is anticipated, a provision is made in the period in which it first becomes evident, for the entire loss anticipated, as assessed by the company's management.

The payment terms in the projects are based on milestones set at the date of signing the contract and are based mainly on the rate of progress. For this reason, the Company is not expected to recognize contract assets or contract liabilities in significant amounts in relation to these contracts.

Financing components

The Company does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the Company does not adjust any of the transaction prices for the time value of money.

N. Assets and liabilities arising from contracts with customers

Contract assets

A contract asset is the Company's right to consideration in exchange for goods or services the entity has transferred to a customer that is conditional on something other than the passage of time.

Trade receivables

A receivable represents the Company's right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due).

O. Property, plant and equipment:

Property and equipment are stated at cost, net of accumulated depreciation and net of impairment. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets at the following rates:

	%
Computer equipment	33
Machinery and equipment	7-20
Vehicles	15

P. Employee benefits:

- 1. Short-term employee benefits: Short-term employee benefits are benefits that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid sick leave, recreation, and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made.
- **2. Post-employment benefits:** The plans are normally financed by contributions to insurance companies and classified as defined contribution plans.

The Company has defined contribution plans pursuant to Section 14 to the Severance Pay Law under which the Company pays fixed contributions to a specific fund and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.

Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense simultaneously with receiving the employee's services and no additional provision is required in the financial statements except for the unpaid contribution.

Q. Operating Segment

The company currently conduct its operation through one operating segment

R. Share-based payments:

Where equity settled share options are awarded to employees, the fair value of the options calculated at the grant date based on the share fair price is charged to the statement of comprehensive income over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each reporting date so that, ultimately, the cumulative amount recognized over the vesting period is based on the number of options that eventually vest. Non-vesting conditions and Market vesting conditions are factored into the fair value of the options granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting condition are satisfied. The cumulative expense is not adjusted for failure to achieve a market vesting condition or where a non-vesting condition is not satisfied.

S. Research and Development:

Costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset when the Company can demonstrate:

• The technical feasibility of completing the intangible asset so that the asset will be available for use or sale

ARBN 619 754 540

Notes to the Financial Statements

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

- Its intention to complete and its ability and intention to use or sell the asset.
- How the asset will generate future economic benefits.
- The availability of resources to complete the asset.
- The ability to measure reliably the expenditure during development.

During the years 2021 and 2020 the company didn't stand in the following criteria therefore all research and development recognized as expenses.

T. Issuance costs:

The company allocated the incremental costs that were directly attributable to issuing new shares to equity (net of any income tax benefit) and the costs that were related to the stock market listing, or are otherwise not incremental and directly attributable to issuing new shares, were recognized as an expense in the statement of comprehensive income. Costs that were related to both share issuance and listing were allocated between those functions based on the number of shares.

U. Earnings (loss) per share:

Earnings per share are calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted number of Ordinary shares outstanding during the period.

Potential Ordinary shares are included in the computation of diluted earnings per share when their conversion decreases earnings per share from net income (loss). Potential Ordinary shares that are converted during the period are included in diluted earnings per share only until the conversion date and from that date in basic earnings per share.

V. Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs (note 2T).

Warrants

Warrants to acquire a fixed number of the Company's own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments.

W. Leases

The company has a contract with lease terms of 12 months or less. The company applies exemptions from the recognition 'short-term lease'.

X. New standards, interpretations and amendments not yet effective

The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.

ARBN 619 754 540

Notes to the Financial Statements

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

IAS1 - Presentation of Financial Statements

In January 2020, the IASB issued amendments to IAS 1, which clarify the criteria used to determine whether liabilities are classified as current or non-current. These amendments clarify that current or non-current classification is based on whether an entity has a right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period. The amendments also clarify that 'settlement' includes the transfer of cash, goods, services, or equity instruments unless the obligation to transfer equity instruments arises from a conversion feature classified as an equity instrument separately from the liability component of a compound financial instrument. The amendments are effective for annual reporting periods beginning on or after 1 January 2022. However, in May 2020, the effective date was deferred to annual reporting periods beginning on or after 1 January 2023.

The Company is currently evaluate the impact of IAS 1 amendments, however, at this stage it is unable to assess such impact.

Onerous Contracts – Costs of Fulfilling a Contract – Amendments to IAS 37

In May 2020, the IASB issued amendments to IAS 37 to specify which costs an entity needs to include when assessing whether a contract is onerous or loss-making.

The amendments apply a "directly related cost approach". The costs that relate directly to a contract to provide goods or services include both incremental costs and an allocation of costs directly related to contract activities. General and administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract.

The amendments are effective for annual reporting periods beginning on or after 1 January 2022.

The Company is currently evaluate the impact of IAS 37 amendments, however, at this stage it is unable to assess such impact.

NOTE 3 - CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS:

The areas requiring the use of estimates and critical judgments that may potentially have a significant impact on the Company's earnings and financial position is Governmental liabilities on grants received.

Governmental liabilities on grants received

The Company measured governmental liabilities on grants received, each period, based on discounted cash flows derived from Company's future anticipated revenues. The discount rate reflect the market rate at the date of receiving the grant. A change in the estimate within a reasonable range will not result a material change of the liability.

ARBN 619 754 540

Notes to the Financial Statements

NOTE 4 - OTHER ACCOUNTS RECEIVABLES:

	As at December 31,	
	2021	2020
	\$'000	\$'000
Government institutions	67	50
Prepaid expenses	153	70
Other receivables	29	71
	249	191

NOTE 5 - OTHER ACCOUNTS PAYABLES:

	As at December 31,	
	2021	2020
	\$'000	\$'000
Employees and related institutions	158	112
Accrued expenses	135	166
Governmental liabilities on grants received (Note 6.C)	25	70
Liabilities to related parties	140	136
Other payables	<u>-</u> _	84
	458	568

NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES:

- A. The Company leases premises for its offices and R&D center in Bet Halevi. The initial contract period ended December 31, 2020. According to the lease agreement, the Company has five consecutive options each for 12 months at its discretion. The company management decision considering the business risk is to evaluate each option at a time, therefore the management estimate a lease period of 12 months during 2022.
 - Total rent expenses for the years ended December 31, 2021 and 2020 were 14 and 11 thousand U.S. dollars respectively.
- B. As of December 31, 2021 and 2020, the Company has a lien in first degree to the bank in amount of approximately 42 and 84 thousands U.S. dollars, respectively on a bank deposit account and all cash and securities deposited in them.
- C. The Company participates in programs sponsored by the Israel Innovation Authority ("IIA"), for the support of several research and development projects programs which subjected to royalties, while others are not (the company is committed to pay royalties for the R&D programs, while the research programs does not required repayment). In exchange for the IIA's participation in the programs, the Company is required to pay royalties to the IIA at a rate of 3% of sales of developed products linked to U.S dollars, until repayment of 100% of the amount of grants received, plus annual interest at the LIBOR rate.

 The Company is required to pay royalties, to the IIA, of sales to end customers of products developed with funds provided by the IIA, if and when such sales are recognized. As of December 31, 2021 and 2020 the Company has not received grants, the aggregate governmental liabilities was 800 thousands U.S. dollars, respectively. The exceptions of the Company to pay the grants are based on its estimation at the end of the each year. During 2021 the company didn't pay royalty to the IIA.

Changes in liabilities arising from financing activities

Reconciliation of the changes in liabilities for which cash flows have been, or will be classified as financing activities in the statement of cash flows:

	Governmental	Derivative
	liabilities on	liability –
	grants received	warrants
	\$'000	\$'000
At 1 January 2021	426	76
Changes from financing cash flows		
Receipt of warrants	-	177
Repayment of short term loans	-	-
Total changes from financing cash flows		177
Changes in fair value	-	(64)
Change in liability	(124)	-
Interest on liability	93	-
The effect of changes in foreign exchange rates	-	-
At 31 December 2021	393	189

ARBN 619 754 540

Notes to the Financial Statements

NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES (CONT.)

	Governmental liabilities on grants received	Derivative liability – warrants	Convertible notes	Short term loan
	\$'000	\$'000	\$'000	\$'000
At 1 January 2020	378	32	178	-
Changes from financing cash flows				
Receipt of short term loans	-	-	-	(242)
Repayment of short term loans		-		59
Total changes from financing cash flows	-	-	-	(183)
Conversion of short term loans to shares	-	-	-	313
Changes in fair value	-	44	(72)	-
Change in liability	(41)	-	-	-
Conversion of convertible notes to shares	-	-	(106)	-
Interest on short term loans	-	-	-	(111)
Interest on liability	89	-	_	-
The effect of changes in foreign exchange rates				(19)
At 31 December 2020	426	76		

NOTE 7 - SHAREHOLDERS EQUITY:

_	Number of shares					
	December 31, 2021		December 31, 2021 Decembe		December	31, 2020
	Authorized	Issued and outstanding	Authorized	Issued and outstanding		
Ordinary shares of NIS 0.01 par value	1,000,000,000	749,632,688	1,000,000,000	539,783,931		
Warrants	5,758,592	5,758,592	5,758,592	5,758,592		

The Ordinary Shares confer upon the holders thereof all rights accruing to a shareholder of the Company, including, the right to receive notices of and to attend meetings of shareholders; for each share held, the right to one vote at all meetings of shareholders; and to share equally, on a per share basis, in such dividend and other distributions to shareholders of the Company as may be declared by the Board of Directors and upon liquidation or dissolution of the Company, in the distribution of assets of the Company legally available for distribution to shareholders in accordance with the terms of applicable law. All Ordinary Shares rank paripassu in all respects with each other.

Notes to the Financial Statements

NOTE 7 - SHAREHOLDERS EQUITY (CONT.):

Movements in ordinary shares:

	2021	2020
	No. of shares	No. of shares
Balance as of January 1	539,783,931	120,764,335
Conversion of short-term loans to shares	-	18,000,000
Conversion of convertible notes to shares	-	5,982,385
Issuance of shares to directors (note 7g)	1,223,125	-
Issuance of shares to stockbroker (note 7h)	42,367,533	-
Issuance of shares to suppliers and employees in lieu of cash payment (note 7i)	6,001,688	27,682,413
Issuance of unit of shares (note 7j)	160,256,411	367,354,798
Balance as of December 31	749,632,688	539,783,931

- **A.** During 2020, the Company issued the following CDIs in lieu of cash payments:
 - a. 4,000,000 CDIs to contractors of the Company on 28 February 2020.
 - b. 12,480,433 CDIs to contractors of the Company on 28 August 2020.
 - c. 4,000,000 CDIs to contractors of the Company on 1 September 2020.
 - d. 2,800,000 CDIs to contractors of the Company on 1 September 2020.
 - e. 2,454,063 CDIs to contractors of the Company on 18 December 2020.
 - f. 1,947,917 CDIs to employee of the Company on 18 December 2020

The Company did this to preserve its cash reserves.

- **B.** In February 2020, the Company announced that it had received firm commitments to raise up to AUD 0.5 million before expenses, by way of a placement of up to 15,151,515 CDIs at AUD 0.033 per CDI to sophisticated and professional investors. Issue of the CDIs was made on 13 February 2020 under the Company's available placement capacities with 2,841,909 CDIs issued under Listing Rule 7.1 and 12,309,606 CDIs issued under Listing Rule 7.1A.
 - Everblu Capital Pty Ltd acted as lead manager for the capital raising and received a fee of 6% of the total funds raised and, subject to receipt of prior shareholder approval to be sought at a future general meeting -2,000,000 CDIs.
- **C.** In May 2020 the Company announced that it had received firm commitments to raise up to AUD 280,000 before expenses, by way of a placement of up to 15,555,556 CDIs at AUD 0.018 per CDI to sophisticated and professional investors. The CDIs were issued on 27 May 2020.
 - Everblu Capital Pty Ltd acted as lead manager for the capital raising and received a fee of 6% of the total funds raised and, subject to receipt of prior shareholder approval to be sought at a future general meeting -1,000,000 CDIs.

ARBN 619 754 540

Notes to the Financial Statements

NOTE 7 - SHAREHOLDERS EQUITY (CONT.):

- **D.** During May 2020, the company approved the issuance of 16,500,000 CDIs to contractors of the Company as stock based compensation. The total fair value of the shares at the amount of \$ 228 thousand was expensed through profit and loss.
- **E.** In August 2020, the Company announced that it had received firm commitments to raise up to AUD 2.510 million before expenses, by way of a placement of up to 156,875,000 CDIs at AUD 0.016 per CDI to sophisticated and professional investors. The CDIs were issued on 27 May 2020.
 - Everblu Capital Pty Ltd acted as lead manager for the capital raising and received a fee of 6% of the total funds raised and, subject to receipt of prior shareholder approval to be sought at a future general meeting -10,000,000 CDIs.
- **F.** In December 2020, the Company announced that it had received firm commitments to raise up to AUD 2.510 million before expenses, by way of a placement of up to 179,772,727 CDIs at AUD 0.022 per CDI to sophisticated and professional investors. The CDIs were issued on 11 December 2020.
 - Everblu Capital Pty Ltd acted as lead manager for the capital raising and received a fee of 6% of the total funds raised and, subject to receipt of prior shareholder approval to be sought at a future general meeting -11,867,553 CDIs.
- **G.** On October 2021, the Company issued 1,223,125 CDIs to Directors for services rendered in lieu of cash fees. This offering was reflected in the financial statements for 2020.
- **H.** On October 2021, the Company issued 42,367,533 CDIs to to Everblu Capital (the Company's Corporate Advisor and Lead Manager) for capital raising and corporate advisory services provided over a period commencing from October 2019 to December 2020.
- **I.** On October 2021, the Company issued 6,001,688 CDIs to contractors of the Company for services rendered in lieu of cash fees.
- J. On December 2021, the Company announced that it had raised AUD1million from Issuance of a unit of securities, before expenses, by way of a placement of up to 160,256,410 CDIs at AUD 0.00624 per CDI to sophisticated and professional investors. In addition, the Company issued option for every CDIs to investors:
 - (1) 40,064,103 options, which have an exercise price of \$0.02, exercisable over a period of 1.7 years.
 - (2) 120,192,308 options (pending approval of the shareholders meeting), which have an exercise price of \$0.0125, exercisable over a period of 1.7 years.

NOTE 7 - SHAREHOLDERS EQUITY (CONT.):

K. Everblu Capital Pty Ltd (EverBlu) acted as Lead Manager to the Offer and as part of its mandate received (pending approval of the shareholders meeting) 40,064,103 Options exercisable over a period of 1.7 years with an exercise price of \$0.02 and 120,192,308 Options over a period of 1.7 years with an exercise prices of \$0.0125, on the same terms as those the subject of the Offer. The value of the 40,064,103 options are \$ 30 and total value of the 120,192,308 options are \$ 146 thousand and as of December 31, 2021 the company recognized as an expense the total value of \$176 thousands. In addition, EverBlu received \$50 thousands in cash.

The options valued using the Black Scholes option valuation methodology based on the following data and assumptions:

Unlisted Options	4,833,333	40,064,103
Share price	AU\$0.009	AU\$0.006
Exercise price	NIS0.01	\$0.02
Risk-free interest rate	1.02%	-
expected average life	5 years	1.7 years

NOTE 8 - SHARE BASED PAYMENT:

A. Options and shares granted to employees and service providers:

	2021		2020	
	Number of Options	Weighted Average Exercise Price NIS	Number of Options	Weighted Average Exercise Price NIS
Options outstanding as beginning of year	1,935,500	0.04	2,083,500	0.04
Changes during the year:				
Granted (1)	4,833,333	0.01	-	0.04
Granted (1)	40,064,103	0.06	-	-
Granted (2)	1,000,000	0.01	-	-
Forfeited	-	-	(148,000)	-
Exercised	-	-	-	-
Options outstanding at end of year	7,768,833	0.04	1,935,500	0.04
Options exercisable at year-end	2,333,000	0.04	1,897,438	0.04
Weighted-average fair value of options Granted during the year				_

^{*} The options outstanding at 31 December 2021 had a weighted-average contractual life of 2 year.

ARBN 619 754 540

Notes to the Financial Statements

NOTE 8 - SHARE BASED PAYMENT (CONT.):

- 1. In October 2021, the Company issued 4,833,333 unlisted options to directors. These options are exercisable over a period of 5 years with an exercise price of NIS0.01. The total value of the options are \$ 27 thousand and as of December 31, 2021 the company recognized as an expense.
- 2. 1,000,000 Listed Options issued to Everblu Capital (the Company's Corporate Advisor and Lead Manager) for capital raising and corporate advisory services provided over a period commencing from October 2019 to December 2020. The value of the options at grant date was AU\$0.0028 each.

B. Performance rights:

The Performance Rights valued using option valuation methodology based on the following data and assumptions:

Data related to the Performance rights as of December 31, 2021 and changes during the two years ended on that date are as follows:

	2021	2020
	Number of rights	
Performance rights outstanding as beginning of year Changes during the year:	16,166,666	19,133,333
Granted (*)	18,000,000	
Forfeited	(2,966,667)	(2,966,667)
Exercised		
Performance rights outstanding at end of year (*)	31,200,000	16,166,666
Performance rights exercisable at year-end	_	2,966,667
Weighted-average fair value of Performance rights Granted during the year		

(*) On September 16, 2021 the company has agreed to issue an aggregate of 18,000,000 Performance Rights to Boaz Wachtel and Sharon Devir, each received 9,000,000 Performance Rights on the terms and conditions set out below:

Class H – 6,000,000 Performance Rights

- a. company executing a joint venture agreement with a company with a synergetic technology to the company
- b. company recording a least AUD\$100,000 pursuant to the joint venture within the first 12 month from the date of execution of the joint venture within 36 months of the date of issue of PR's.

ARBN 619 754 540

Notes to the Financial Statements

NOTE 8 - SHARE BASED PAYMENT (CONT.):

Class I - 6,000,000 Performance Rights

Company recording gross sales of AUD\$500,000 within 18 months of the date of issue of PR's.

Class J - 6,000,000 Performance Rights

Company recording gross sales of AU\$300,000 as a result of signing letter of intent or definitive dealership agreement in at least 3 new territories within 24 months of the date of issue of PR's.

The value of the Performance Rights was valued based on share price as of the date of the issuance, in a total amount of \$120 thousand., and was expensed during the period.

NOTE 9 - LOSS PER SHARE:

Net loss per share attributable to equity owners:

	For the year ended December 31,	
	2021 \$'000	2020 \$'000
Net loss used in basic and diluted EPS	(2,319)	(3,202)
Weighted average number of shares used in basic and diluted EPS	556,831,758	227,654,071
Basic and diluted net EPS (dollars)	(0.006)	(0.014)

At 31 December 2021, 31,200,000 Performance Rights and 47,832,936 options (2020: 16,166,666 Performance Rights and 1,935,500 options) were excluded from the diluted weighted-average number of ordinary shares calculation because their effect would have been anti-dilutive.

ARBN 619 754 540

Notes to the Financial Statements

NOTE 10 - REVENUE:

	For the year ended December 31,	
	2021	2020
Primary Geographic Markets	\$'000	\$'000
Asia	59	-
Australia	6	-
America	41	-
Israel	81	107
Total	187	107

All revenues were derived from 10 customers

NOTE 11 - RESEARCH AND DEVELOPMENT EXPENSES, NET:

	For the year ended December 31,	
	2021	2020
	\$'000	\$'000
Salaries and benefits	419	147
Subcontractors	70	157
Materials	89	16
Legal fees	31	60
Other	5	10
	614	390
Governmental Grants received and changes in liability, net	(124)	(41)
Total	490	349

NOTE 12- MARKETING, DISTRIBUTION AND BUSINESS DEVELOPMENT EXPENSES:

	For the year ended December 31,		
	2021 \$'000	2020 \$'000	
Business development	213	400	
Salaries and benefits	338	233	
Marketing	-	47	
Other	54	71	
Total	605	751	

ARBN 619 754 540

Notes to the Financial Statements

NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES:

	For the year ended December 31,		
	2021	2020	
	\$'000	\$'000	
Salaries and benefits	172	102	
Share based payment	147	225	
Consulting	267	368	
Public Relations	77	893	
Professional fees	178	144	
Insurance	51	58	
Rental and office expenses	48	35	
Refreshments	11	9	
Advertising	134	7	
Other	71	68	
Total	1,156	1,909	

NOTE 14 - FINANCE EXPENSE AND INCOME:

Finance expense:

	For the year ended December 31,		
	2021	2020	
	\$'000	\$'000	
Changes in fair value of convertible notes	-	13	
Net foreign exchange loss	32	-	
Interest on governmental liabilities on grants received	92	89	
Interest and bank charges and other	4	100	
Capital issuance fees	78	3	
Changes in fair value of derivative liability – warrants		46	
Total finance expense	206	<u>251</u>	

Finance income:

	For the year ended December 31,		
	2021	2020	
	\$'000	\$'000	
Changes in fair value of derivative liability – warrants	68	-	
Net foreign exchange gain	<u> </u>	45	
Total finance income	68	45	

ARBN 619 754 540

Notes to the Financial Statements

NOTE 15 - TAXATION:

A. Israeli tax rates:

Israeli corporate tax rates are 23%.

B. Net operating losses carry forward:

As of December 31, 2021, the Company has estimated carry forward tax losses of approximately 15,891 thousand U.S. dollars, which may be carried forward and offset against taxable income for an indefinite period in the future. Deferred tax asset on the company's losses was not recognized since it is not probable that taxable profit will be available in the foreseen future.

C. Reconciliation of effective tax rate:

The adjustments for the difference between the actual tax charge for the year and the standard rate of corporation tax in Israel applied to profits for the year are as follows:

	For the year ended December 31,		
	2021	2020	
	\$'000	\$'000	
Loss before income tax	(2,319)	(3,202)	
Tax computed at the corporate rate in Israel	533	736	
losses for which no deferred tax asset is recognized	(533)	(736)	
Total income tax expense			

Notes to the Financial Statements

NOTE 16 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT:

The Company holds the following financial instruments:

2021	
\$'000	\$'000
1,424	3,067
42	84
62	68
29	71
1,557	3,290
2021	2020
\$'000	\$'000
303	388
414	426
717	814
189	76
189	<u>76</u>
	\$'000 1,424 42 62 29 1,557 2021 \$'000 303 414 717

The Company is expose to variety of financial risks, which results from its financing, operating and investing activities. The objective of financial risk management is to contain, where appropriate, exposures in these financial risks to limit any negative impact on the Company's financial performance and position. The Company's financial instruments are its cash, trade and other receivables, trade payables and other liabilities. The main purpose of these financial instruments is to raise finance for the Company's operation. The Company actively measures, monitors and manages its financial risk exposures by various functions pursuant to the segregation of duties and principals. The risks arising from the Company's financial instruments are mainly credit risk, currency risk and liquidity risk. The Company has no interest rate risk as the balances exposure to interest is minimal. The risk management policies employed by the Company to manage these risks discussed below.

A. Credit risk:

Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities (primarily trade receivables) and from deposits with banks and financial institutions and other financial instruments.

NOTE 16 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONT.):

Trade receivables and contract assets

The Company believes that there is no material credit risk in light of Company's policy to assess the credit risk instruments of customers before entering contracts. Credit quality of a customer is assessed based on an extensive credit rating scorecard and individual credit limits are defined in accordance with this assessment.

Cash and cash equivalents and deposits with banks

The Company holds cash and cash equivalents and deposit accounts in big banking institutions in Israel and in the Australia, thereby substantially reducing the risk to suffer credit loss

B. Foreign currency risk:

Foreign exchange risk arises when the company enter into transactions denominated in a currency other than its functional currency. The company is exposed to currency risk to the extent that there is a mismatch between the currency in which it denominated and the respective functional currency of the company.

The currencies in which some transactions are primarily denominated are US dollars and Australian dollars.

The company's policy is not to enter into any currency hedging transactions. The carrying amounts of the Company's foreign currency denominated monetary assets and monetary liabilities at the reporting date are as follows:

	As	at December 3	31, 2021	
Assets	US dollar	AUD	NIS	Total
Cash And cash equivalents	24	1,368	32	1,424
Restricted cash	-	-	42	42
Trade receivables	48	-	14	62
Other accounts receivables			29	29
	72	1,368	117	1,557
Liabilities				
Trade and other payables	41	34	228	303
Derivative liability – warrants	-	189	-	189
Governmental liabilities on grants received	393	-	-	393
	434	223	228	885

NOTE 16 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONT.):

	As at December 31, 2020				
Assets	US dollar	AUD	NIS	Total	
Cash And cash equivalents	27	2,871	169	3,067	
Restricted cash	-	-	84	84	
Trade receivables	48	-	20	68	
Other accounts receivables	58	<u>-</u>	13	71	
	133	2,871	286	3,290	
Liabilities					
Trade and other payables	18	130	240	388	
Derivative liability – warrants	-	76	-	76	
Governmental liabilities on grants received	426	-	-	426	
	444	206	240	890	

Analysis:

A 5% strengthening of the NIS against the following currencies would have increased (decreased) equity and the income statement by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. For a 5% weakening of the NIS against the relevant currency, there would be an equal and opposite impact on the profit and other equity.

	2021	2020
Linked to US dollar	(362)	(311)
	5%	5%
	18	16
Linked to AUD	1,145	2,665
	5%	5%
	57	133

C. Liquidity risks:

Liquidity risk is the risk that arises when the maturity of assets and the maturity of liabilities do not match. An unmatched position potentially enhances profitability but can also increase the risk of loss. The Company has procedures with the object of minimizing such loss by maintaining sufficient cash and other highly liquid current assets and by having available an adequate amount of committed credit facilities. The Company has no material obligation beyond one year (the liabilities for governmental institutes depends on achieving future revenues) and has a negative working capital and cash in bank to finance its working capital in the near future.

ARBN 619 754 540

Notes to the Financial Statements

NOTE 16 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONT.):

The table below summarizes the maturity profile of the Company's financial liabilities based on contractual undiscounted payments except for governmental liabilities on grants received which based on the repayment forecast of the management of the company

December 31, 2021:

, , ,	Amortized cost						
	Book value	Less than one year	1 to 2 years	2 to 3 years	3 to 4 years	> 5 years	Total
-	U.S. dollars in thousands						
Derivative liability – warrants	(189)	(12)	(30)	(147)	-	-	(189)
Trade and other accounts payables	(303)	(303)	-	-	-	-	(303)
Governmental liabilities on grants received	(393)	(30)	(90)	(180)	(270)	(230)	(800)
Total	(885)	(345)	(120)	(327)	(270)	(230)	(1,292)

December 31, 2020:

	Amortized cost						
	Book	Less than	1 to 2	2 to 3	3 to 4	> 5	
_	value	one year	years	years	years	years	Total
			U.S.	dollars in th	ousands		
Derivative liability –							
warrants	(76)	-	(76)	-	-	-	(76)
Trade and other accounts							
payables	(388)	(388)		-	-	-	(388)
Governmental liabilities	(10.5)	(=0)	(4.4.5)	(22.1)	(202)		(2.50)
on grants received	(426)	(70)	(146)	(234)	(302)	_	(752)
Total	(890)	(458)	(222)	(234)	(302)		(1,216)

D. Fair value of financial assets and liabilities:

Fair value measurements using input type

	U.S. \$ in thousands			
	Level 1	Level 2	Level 3	Total
As of December 31, 2021				
Warrants (issuance of a unit of securities) **	12	-	-	12
Warrants (issuance of a unit of securities)	-	-	177	177
As of December 31, 2020				
Warrants (issuance of a unit of securities)**	76	-	-	76

^{**}The warrants (issuance of a unit of securities) are trading under the ASX code ROOO

ARBN 619 754 540

Notes to the Financial Statements

NOTE 16 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONT.)

The fair value measurement of the warrants in the table above, was estimated using a Monte Carlo simulation analysis, based on a variety of significant unobservable inputs and thus represent a level 3 measurement within the fair value hierarchy. As of the issue date of the warrants, the key inputs that were used in measuring the fair value of the Convertible notes were: the risk free interest rate- 1.7%, the expected volatility-75% and the AUD/USD exchange rate -0.7088.

The following table summarizes the quantitative information about the significant unobservable inputs used in level 3 fair value measurements:

31.12.2021

	Fair			Relationship of unobservable
Item	value	Unobservable inputs	Inputs	inputs to fair value
	U.S. \$ in			-
	thousands			
Warrants	177	Volatility of firm's assets	75%	A change in the volatility measure by %5 results in a
		returns		change of +/- 12K of the fair value

Reconciliation of fair value measurements that are categorized within Level 3 of the fair value hierarchy:

	2021	2020		
Convertible notes	U.S. \$ in the	U.S. \$ in thousands		
Balance as of January 1	-	178		
Conversion of convertible notes to shares	-	(106)		
Net loss recognized in Profit or loss	<u>-</u> _	(72)		
Balance as of December 31	<u> </u>	-		
Warrants				
Balance as of January 1	-	-		
Issuance of warrants	177	-		
Net loss recognized in Profit or loss	<u>-</u> _			
Balance as of December 31	177	-		

ARBN 619 754 540

Notes to the Financial Statements

NOTE 16 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONT.)

E. Financial instruments not measured at fair value:

Financial instruments not measured at fair value includes cash and cash equivalents, restricted cash, trade and other receivables, trade and other payables, and governmental liabilities on grants received.

Due to their short-term nature, the carrying value of cash and cash equivalents, restricted cash, trade and other receivables, trade and other payables approximates their fair value.

The fair value of governmental liabilities on grants received for December 31, 2021 and December 31, 2020 is not materially different to the carrying amount, since the interest rate used in the initial recognition is close to current market rates.

F. The Group's objectives when maintaining capital are:

The Company seeks to maintain a capital structure which enables it to continue as a going concern and which supports its business strategy. The Company's capital is provided by equity rising. The Company manages its capital structure through raising funds from shareholders. The Company has net cash and cash equivalents at the balance sheet date of 1,424 (2020 - 3,067) thousands U.S. dollars. Accordingly, the directors believe that the company will be able to pay its debts when they fall due, and to fund near term anticipated activities based on receipt from issuance of shares in addition to revenues backlog.

NOTE 17 - RELATED PARTY AND SHAERHOLDRS:

Related party transactions:

	December 31,	
	2021	2020
Compensation of key management personnel of the Company:	\$'000	\$'000
Short-term employee benefits *)	440	171

^{*)} Including Management fees for the CEO, Directors Executive Management and other related parties.

Balances with related parties:

Trade

As at Dece	mber 31,
2021	2020
\$'000	\$'000
-	81

ARBN 619 754 540

Notes to the Financial Statements

NOTE 18 - EMPLOYEE BENEFITS:

The Company has defined contribution plans pursuant to Section 14 to the Severance Pay Law under which the Company pays fixed contributions to a specific fund and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.

	Year ended December 31,	
	2021	2020
	\$'000	\$'000
Expenses in respect of defined contribution plans	77	39